Abiopharma

Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid

Dupixent® (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP)

Q & M Dental Group (Singapore) Limited - Announcement

Netflix’s Movie Momentum in 2025: Big Names and Blockbusters

Employee Stock Option/ Share Scheme: ISSUANCE OF SHARES PURSUANT TO ENTERPRISE OPTION SCHEME

NASDAQ traded attribute type Security_Name was changed. Previous value: Lipella Pharmaceuticals Inc. - Common Stock. New value: Lipella Pharmaceuticals Inc. - Common Stock.

NASDAQ traded attribute type Test_mode was changed. Previous value: N. New value: Lipella Pharmaceuticals Inc. - Common Stock.

NASDAQ traded attribute type Financial_Status was changed. Previous value: N. New value: Lipella Pharmaceuticals Inc. - Common Stock.

Cygnus raises $18.3m to accelerate resource growth and mining studies

Cygnus lève 18,3 M$ pour accélérer la croissance de ses ressources et ses études minières

Madison Pacific Properties Inc. (TSX: MPC and MPC.C) announces results of Annual General Meeting

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Belo Sun Announces Planned Executive Leadership Transition

Dundee Corporation Announces Voting Results from 2025 Annual Meeting of Shareholders

Independent Proxy Advisory Firm ISS Recommends MAG Silver Corp. Shareholders Vote “FOR” the Plan of Arrangement With Pan American Silver Corp.